Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023

Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023

Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.

Researcher experts consider it as an autoimmune disease in which the body turns against its own cells and the exact cause is unknown. Researchers believe this autoimmune response may be triggered by environmental and genetic factors.

Primary Biliary Cirrhosis symptoms included dry eyes and mouth, spleen swelling, joint pain, buildup of fluid in the abdomen, jaundice, fatigue and itchy skin.

Blood tests including liver test, antibody test and cholesterol test may be used to diagnose primary biliary cirrhosis. Imaging tests looking at the liver and bile ducts may include fibroscan, ultrasound, MRCP and magnetic resonance elastopraphy.

Treatment of PBC include treating the disease with medications like ursodeoxycholic acid, obeticholic acid symptoms, fibrates and budesonide. Treating the symptoms like fatigue dry eyes and mouth may also alleviate the disease condition.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Primary Biliary Cirrhosis treatment such as Elafibranor, Linerixibat, Setanaxib and others. Key players involved in the development of therapies to treat Primary Biliary Cirrhosis are Albireo, Calliditas Therapeutics AB, Genfit, GlaxoSmithKline, Merck Sharp & Dohme LLC and others. Six drugs are under late-stage Phase III clinical trials and nine drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Primary Biliary Cirrhosis (Primary Biliary Cholangitis) - Drug Pipeline Landscape, 2023 report provides an overview of the Primary Biliary Cirrhosis pipeline drugs. This report covers detailed insights on Primary Biliary Cirrhosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Primary Biliary Cirrhosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.